Eli Lilly and Incyte's Olumiant has secured the first FDA approval for a systemic drug to treat alopecia areata, an autoimmune condition causing patchy hair loss that affects more than 700,000 ...

Eli Lilly and Incyte have another rival in the rear-view mirror for Olumiant in alopecia areata after Pfizer reported that its ritlecitinib improved scalp hair regrowth in a late-stage trial.

Lower serum levels of both vitamin D and zinc were associated with an increased risk of alopecia areata, but no significant difference in alopecia areata risk was observed for serum copper levels.

Alopecia areata (al-uh-PEE-shuh air-ee-AH-tuh) is a condition that causes hair loss on the scalp and sometimes elsewhere on the body, such as the eyebrows and eyelashes. The condition is not ...

Leqselvi is now FDA approved for treating severe alopecia areata. Sun Pharma added the ... were it will compete against Eli Lilly’s Olumiant. Sun Pharmaceuticals is acquiring Concert ...

Alopecia areata (al-uh-PEE-shuh air-ee-AH-tuh) is a condition that causes hair loss on the scalp and sometimes elsewhere on the body. Both boys and girls can get alopecia areata, which can begin at ...

DelveInsight's Alopecia Areata Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM. LAS VEGAS, NV, UNITED STATES, January 15, 2025 /EINPresswire ...